Allergan CEO Saunders defends Restasis deal by calling for review of patent challenge process
admin 3rd October 2017 Uncategorised 0Facing a barrage of negative pricing attention earlier this year, pharmaceutical trade group PhRMA overhauled its membership criteria in a move to bolster the research-based industry’s image. Now, Sen. Claire McCaskill is wondering whether Allergan’s recent tribal licensing agreement is in agreement with those efforts.
More: Allergan CEO Saunders defends Restasis deal by calling for review of patent challenge process
Source: fierce